Lung Cancer
A Phase II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, pharmacokinetics, and recommended combination dose of BNT324 with BNT327 in participants with advanced lung cancer. BNT324-01
- Details
ClinicalTrials.gov ID:
NCT06892548
Diagnosis Type:
NA
USOR Number:
- Address
,
P: